By Dr. Priyom Bose, Ph.D.Reviewed by Danielle Ellis, B.Sc. How does semaglutide work?Emerging trends in semaglutide researchBrain healthCardiovascular benefitsKidney healthCommercial availability and challengesReferencesFurther reading Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current research findings and clinical trials have...
Tag: <span>Semaglutide</span>
Post
Eye Complications Found With Use of Semaglutide, Tirzepatide
Edited by Shrabasti Bhattacharya February 07, 2025 4312 Add to Email Alerts TOPLINE: At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic optic neuropathy (NAION), according to a case series. Researchers hypothesize that rapid correction of hyperglycemia induced by...
Post
What’s Next for Semaglutide? Beyond Diabetes and Weight Loss
By Dr. Priyom Bose, Ph.D.Reviewed by Danielle Ellis, B.Sc. How does semaglutide work?Emerging trends in semaglutide researchBrain healthCardiovascular benefitsKidney healthCommercial availability and challengesReferencesFurther reading Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current research findings and clinical trials have...
Post
Eye Complications Found With Use of Semaglutide, Tirzepatide
Edited by Shrabasti Bhattacharya February 07, 2025 2285 TOPLINE: At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic optic neuropathy (NAION), according to a case series. Researchers hypothesize that rapid correction of hyperglycemia induced by these drugs may be...
Post
Six Substudies From the Semaglutide Trials: Identifying Mechanisms of Benefit and Whom to Treat
Identifying Mechanisms of Benefit and Whom to Treat Neha J. Pagidipati, MD, MPHDisclosures J Am Coll Cardiol. 2024;84(17) 27 Add to Email Alerts Several trials have documented the cardiovascular (CV) benefits of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide, including the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), STEP-HFpEF (Effect...
Post
Six Substudies From the Semaglutide Trials: Identifying Mechanisms of Benefit and Whom to Treat
Identifying Mechanisms of Benefit and Whom to Treat Neha J. Pagidipati, MD, MPHDisclosures J Am Coll Cardiol. 2024;84(17) 11 Added to Email Alerts Several trials have documented the cardiovascular (CV) benefits of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide, including the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), STEP-HFpEF (Effect...
Post
Semaglutide Rocketing Past Statins as Millions Eligible
Alicia Ault November 27, 2024 0178 Added to Email Alert About 40% of American adults — some 137 million — are eligible to take the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide, said authors of a new study. Currently, statins are the most commonly prescribed medication for American adults, with some 192 million prescriptions written...
Post
More Evidence Ties Semaglutide to Reduced Alzheimer’s Risk
A new study provides real-world evidence to support the potential repurposing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), used to treat type 2 diabetes and obesity, for prevention of Alzheimer’s disease (AD). Adults with type 2 diabetes who were prescribed the GLP-1 RA semaglutide had a significantly lower risk for AD compared with their peers who were prescribed any of...
Post
Popular diabetes and weight-loss drug may reduce risk of Alzheimer’s disease
by Case Western Reserve University Credit: SHVETS production from Pexels Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type 2 diabetes (T2D). Alzheimer’s disease is a brain disorder...
Post
How Are Doctors Using Tirzepatide vs Semaglutide? A Q&A
When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c reduction. Studies indicated that tirzepatide can lead to greater weight loss than semaglutide. Factors like insurance coverage, drug availability, and side effects also influence physicians’ choices, with some patients...